Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: Dose association with all-cause mortality, cardiovascular events and cancer

Diabetes, Obesity and Metabolism

Volumn 17, Issue 4, 2015, Pages 350-362

  Holden, S E ^a   Jenkins Jones, S ^b   Morgan, C Ll ^b   Schernthaner, G ^c   Currie, C J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Global Epidemiology   (United Kingdom)

^c KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

All cause mortality; Cancer; Dose; Epidemiology; Insulin; Major adverse cardiovascular events; Type 2 diabetes

Indexed keywords

CREATININE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHARLSON COMORBIDITY INDEX; CREATININE BLOOD LEVEL; DUST EXPOSURE; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; TREATMENT DURATION; BLOOD; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; DOSE RESPONSE; ELECTRONIC HEALTH RECORD; GREAT BRITAIN; HYPERGLYCEMIA; INCIDENCE; MORTALITY; NEOPLASMS; PROPORTIONAL HAZARDS MODEL; RISK;

AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRONIC HEALTH RECORDS; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; MALE; MIDDLE AGED; MORTALITY; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK;

EID: 84924733192     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12412     Document Type: Article

References (43)

1. Holden SE, Gale EAM, Jenkins-Jones S, Currie CJ. How many people inject insulin? UK estimates from 1991 to 2010. Diabetes Obes Metab 2014; 16: 533-539.
2. Holden S, Poole C, Morgan C, Currie CJ. Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin. BMJ Open 2011; 1: e000258.
3. National Institute for Heath and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 87. 2009. Available from URL: http://www.nice.org.uk/guidance/cg87. Accessed 20 November 2014.
4. Currie CJ, Peters JR, Tynan A et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375: 481-489.
5. Nichols G, Joshua-Gotlib S, Parasuraman S. Glycemic control and risk of cardiovascular disease hospitalization and all-cause mortality. J Am Coll Cardiol 2013; 62: 121-127.
6. Monami M, Vitale V, Lamanna C et al. HbA1c levels and all-cause mortality in type 2 diabetic patients: epidemiological evidence of the need for personalised therapeutic targets. Nutr Metab Cardiovasc Dis 2013; 23: 300-306.
7. Colayco D, Niu F, McCombs J, Cheetham TC. A1C and cardiovascular outcomes in type 2 diabetes. Diabetes Care 2011; 34: 77-83.
8. Ostgren CJ, Sundström J, Svennblad B, Lohm L, Nilsson PM, Johansson G. Associations of HbA1c and educational level with risk of cardiovascular events in 32 871 drug-treated patients with type 2 diabetes: a cohort study in primary care. Diabet Med 2013; 30: e170-e177.
9. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
10. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
11. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343: d4169.
12. Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2009; 19: 604-612.
13. Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab 2013; 98: 668-777.
14. Gamble J-M, Simpson SH, Eurich DT, Majumdar SR, Johnson JA. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab 2010; 12: 47-53.
15. Eurich DT, Simpson S, Senthilselvan A, Asche CV, Sandhu-Minhas JK, McAlister FA. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ 2013; 346: f2267.
16. Clinical Practice Research Datalink (CPRD). Clinical Practice Research Datalink. 2013. Available from URL: http://www.cprd.com/intro.asp. Accessed 19 November 2014.
17. Charlson M, Pompei P, Ales K, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
18. Gallagher EJ, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 2010; 21: 610-618.
19. Muis MJ, Bots ML, Grobbee DE, Stolk RP. Insulin treatment and cardiovascular disease; friend or foe? A point of view. Diabet Med 2005; 22: 118-126.
20. Cao W, Ning J, Yang X, Liu Z. Excess exposure to insulin is the primary cause of insulin resistance and its associated atherosclerosis. Curr Mol Pharmacol 2011; 4: 154-166.
21. Ruige JB, Assendelft WJJ, Dekker JM et al. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 1998; 97: 996-1001.
22. Gupta N, Park E, Sandhu H, Goh T, Tchipashvili V, Giacca A. Direct and indirect effects of insulin on hepatic glucose production in diabetic depancreatized dogs during euglycemia. J Endocrinol 2006; 190: 695-702.
23. Kruszynska YT, Home PD, Alberti KGMM. Comparison of portal and peripheral insulin delivery on carbohydrate metabolism in streptozotocin-diabetic rats. Diabetologia 1985; 28: 167-171.
24. Nordin C. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia 2010; 53: 1552-1561.
25. Chow E, Bernjak A, Williams S et al. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes 2014; 63: 1738-1747.
26. Stahn A, Pistrosch F, Ganz X et al. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias. Diabetes Care 2014; 37: 516-520.
27. Rubin DJ, Rybin D, Doros G, McDonnell ME. Weight-based, insulin dose-related hypoglycemia in hospitalized patients with diabetes. Diabetes Care 2011; 34: 1723-1728.
28. ORIGIN Trial Investigators, Gerstein HC, Bosch J et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328.
29. The ORIGIN Trial Investigators. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 2013; 34: 3137-3144.
30. Margolis DJ, Ma OH, Strom BL. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 2008; 17: 753-759.
31. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Rydén L, DIGAMI 2 Investigators. Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. Diabetologia 2011; 54: 1308-1317.
32. Malmberg K, Rydén L, Wedel H et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005; 26: 650-661.
33. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254-258.
34. Yang Y, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004; 127: 1044-1050.
35. Bowker SL, Yasui Y, Veugelers P, Johnson JA. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 2010; 53: 1631-1637.
36. Karlstad O, Starup-Linde J, Vestergaard P et al. Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. Curr Drug Saf 2013; 8: 333-348.
37. Mogensen UM, Andersson C, Fosbøl EL et al. Cardiovascular safety of combination therapies with incretin based drugs and metformin compared with a combination of metformin and sulfonylurea in type 2 diabetes mellitus - a retrospective nationwide study. Diabetes Obes Metab 2014; 16: 1001-1008.
38. Pyorala M, Miettinen H, Halonen P, Laakso M, Pyörälä K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 2000; 20: 538-544.
39. Bonora E, Formentini G, Calcaterra S et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Diabetes Care 2002; 25: 1135-1141.
40. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-846.
41. Hawa MI, Buchan AP, Ola T et al. LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes. Diabetes Care 2014; 37: 1643-1649.
42. Center for Drug Evaluation and Research. Medical Review(s). Application Number: 21-536. 2005. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021-536_Levemir_medr.PDF. Accessed 22 August 2014.
43. Currie CJ, Holden SE. Optimising clinical outcomes resulting from glucose lowering therapies in type 2 diabetes: increased confidence about the DPP-4 inhibitors and continued concerns regarding sulfonylureas and exogenous insulin. Diabetes Obes Metab 2014; 16: 881-884.